| Detection of circulating tumor DNA in early-and late-stage human malignancies C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ... Science translational medicine 6 (224), 224ra24-224ra24, 2014 | 5079 | 2014 |
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ... Nature 486 (7404), 532-536, 2012 | 2103 | 2012 |
| Integrating liquid biopsies into the management of cancer G Siravegna, S Marsoni, S Siena, A Bardelli Nature reviews Clinical oncology 14 (9), 531-548, 2017 | 1924 | 2017 |
| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015 | 1161 | 2015 |
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016 | 1043 | 2016 |
| Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition AN Hata, MJ Niederst, HL Archibald, M Gomez-Caraballo, FM Siddiqui, ... Nature medicine 22 (3), 262-269, 2016 | 995 | 2016 |
| Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... Cancer discovery 3 (6), 658-673, 2013 | 719 | 2013 |
| Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth G Germano, S Lamba, G Rospo, L Barault, A Magrì, F Maione, M Russo, ... Nature 552 (7683), 116-120, 2017 | 629 | 2017 |
| Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma L Goyal, SK Saha, LY Liu, G Siravegna, I Leshchiner, LG Ahronian, ... Cancer discovery 7 (3), 252-263, 2017 | 525* | 2017 |
| Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers AR Parikh, I Leshchiner, L Elagina, L Goyal, C Levovitz, G Siravegna, ... Nature medicine 25 (9), 1415-1421, 2019 | 459 | 2019 |
| Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer M Russo, G Siravegna, LS Blaszkowsky, G Corti, G Crisafulli, ... Cancer discovery 6 (2), 147-153, 2016 | 425 | 2016 |
| Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK … N Tanaka, JJ Lin, C Li, MB Ryan, J Zhang, LA Kiedrowski, AG Michel, ... Cancer discovery 11 (8), 1913-1922, 2021 | 389 | 2021 |
| How liquid biopsies can change clinical practice in oncology G Siravegna, B Mussolin, T Venesio, S Marsoni, J Seoane, C Dive, ... Annals of Oncology 30 (10), 1580-1590, 2019 | 332 | 2019 |
| TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma L Goyal, L Shi, LY Liu, F Fece de la Cruz, JK Lennerz, S Raghavan, ... Cancer discovery 9 (8), 1064-1079, 2019 | 327 | 2019 |
| Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer M Russo, S Misale, G Wei, G Siravegna, G Crisafulli, L Lazzari, G Corti, ... Cancer discovery 6 (1), 36-44, 2016 | 314 | 2016 |
| Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ... Science translational medicine 6 (224), 224ra26-224ra26, 2014 | 305 | 2014 |
| Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer S Arena, B Bellosillo, G Siravegna, A Martínez, I Canadas, L Lazzari, ... Clinical cancer research 21 (9), 2157-2166, 2015 | 298 | 2015 |
| Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer AR Parikh, EE Van Seventer, G Siravegna, AV Hartwig, A Jaimovich, Y He, ... Clinical Cancer Research 27 (20), 5586-5594, 2021 | 289 | 2021 |
| Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer L Barault, A Amatu, G Siravegna, A Ponzetti, S Moran, A Cassingena, ... Gut 67 (11), 1995-2005, 2018 | 234 | 2018 |
| Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer BO Van Emburgh, S Arena, G Siravegna, L Lazzari, G Crisafulli, G Corti, ... Nature communications 7 (1), 13665, 2016 | 215 | 2016 |
